Ubs Group Ag Intra Cellular Therapies, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 56,211 shares of ITCI stock, worth $4.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,211

Previous 47,104 19.33%

Holding current value

$4.78 Million

Previous $3.23 Million 27.4%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$67.99 - $80.84 $619,184 - $736,209	9,107 Added 19.33%	56,211 $4.11 Million
Q2 2024 Aug 13, 2024	SELL	$64.76 - $79.84 $5.82 Million - $7.18 Million	-89,892 Reduced 65.62%	47,104 $3.23 Million
Q1 2024 May 13, 2024	BUY	$64.37 - $75.65 $143,802 - $169,002	2,234 Added 1.66%	136,996 $9.48 Million
Q4 2023 Feb 09, 2024	BUY	$46.37 - $73.65 $4.2 Million - $6.67 Million	90,617 Added 205.27%	134,762 $9.65 Million
Q3 2023 Nov 09, 2023	SELL	$52.09 - $64.1 $1.59 Million - $1.96 Million	-30,553 Reduced 40.9%	44,145 $2.3 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $1.91 Million - $2.32 Million	34,924 Added 87.81%	74,698 $4.73 Million
Q1 2023 May 12, 2023	BUY	$43.8 - $56.99 $473,872 - $616,574	10,819 Added 37.36%	39,774 $2.15 Million
Q4 2022 Feb 08, 2023	BUY	$44.07 - $54.45 $1.16 Million - $1.43 Million	26,349 Added 1011.09%	28,955 $1.53 Million
Q3 2022 Nov 10, 2022	SELL	$42.7 - $59.99 $40,266 - $56,570	-943 Reduced 26.57%	2,606 $121,000
Q2 2022 Aug 10, 2022	SELL	$43.0 - $65.64 $2.48 Million - $3.79 Million	-57,671 Reduced 94.2%	3,549 $203,000
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $804,707 - $1.29 Million	20,772 Added 51.35%	61,220 $3.75 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $1.31 Million - $1.98 Million	37,098 Added 1107.4%	40,448 $2.12 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $275,941 - $408,243	-9,608 Reduced 74.15%	3,350 $125,000
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $190,567 - $289,428	-6,504 Reduced 33.42%	12,958 $529,000
Q1 2021 May 12, 2021	SELL	$30.8 - $39.51 $3,819 - $4,899	-124 Reduced 0.63%	19,462 $661,000
Q4 2020 Feb 11, 2021	BUY	$23.34 - $32.22 $359,109 - $495,736	15,386 Added 366.33%	19,586 $622,000
Q3 2020 Nov 12, 2020	SELL	$17.61 - $31.86 $281,777 - $509,791	-16,001 Reduced 79.21%	4,200 $108,000
Q2 2020 Jul 31, 2020	SELL	$14.35 - $26.64 $427,543 - $793,712	-29,794 Reduced 59.59%	20,201 $518,000
Q1 2020 May 01, 2020	SELL	$12.31 - $33.12 $278,476 - $749,240	-22,622 Reduced 31.15%	49,995 $768,000
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $475,653 - $2.52 Million	65,517 Added 922.77%	72,617 $2.49 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $9,711 - $18,239	-1,300 Reduced 15.48%	7,100 $53,000
Q2 2019 Aug 14, 2019	SELL	$10.65 - $14.29 $37,157 - $49,857	-3,489 Reduced 29.35%	8,400 $109,000
Q1 2019 May 14, 2019	BUY	$10.9 - $14.09 $29,898 - $38,648	2,743 Added 29.99%	11,889 $145,000
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $88,536 - $179,124	8,546 Added 1424.33%	9,146 $104,000
Q3 2018 Nov 14, 2018	SELL	$17.77 - $22.9 $2,985 - $3,847	-168 Reduced 21.88%	600 $13,000
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $20,674 - $27,916	-1,193 Reduced 60.84%	768 $14,000
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $20,632 - $34,691	1,361 Added 226.83%	1,961 $41,000
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $150,691 - $177,302	-10,560 Reduced 94.62%	600 $9,000
Q3 2017 Nov 14, 2017	SELL	$10.77 - $22.1 $32,999 - $67,714	-3,064 Reduced 21.54%	11,160 $177,000
Q2 2017 Aug 14, 2017	BUY	N/A	14,124 Added 14124.0%	14,224 $176,000
Q1 2017 Nov 14, 2017	BUY	N/A	100	100 $2,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.02B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account